Filbanserin, a proposed drug for Female Sexual Interest Arousal Disorder, was rejected by the FDA in December, according to Cleveland’s Plain Dealer. The FDA rejected its approval because the drug only should moderate success rates.
Filbanserin, a proposed drug for Female Sexual Interest/Arousal Disorder, was rejected by the FDA in December, according to Cleveland’s Plain Dealer. The FDA rejected its approval because the drug achieved a moderate success rates. Sprout Pharmaceuticals, one of the companies racing to create a “female Viagra,” wants the repeal the decision. The Food and Drug Administration rejected Filbanserin a few years ago for the same reason.
Female Sexual Interest/Arousal Disorder was added to the DSM-V. It became the female version of HSDD or Hypoactive Sexual Desire Disorder. One mental health professional condemned the disorder as being tailor-made for the pharmaceutical industry.
Pharmaceutical companies want to create an HSDD drug to tap into an estimated $1 billion market. Pursuing these drugs furthers the belief that asexuals suffer from a physical or mental defect. Popular culture has done little to help. Even the medical drama House suggested that asexuals were either lying or suffering from a brain tumor.
Other HSDD drugs, such as Libigel, were rejected due to safety concerns. Libigel was a low-dose testosterone gel designed to increase libido in post-menopausal women. Filbanserin works by increasing serotonin levels. A recent study showed that increasing serotonin levels can improve arousal.